These findings highlight the efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing HbA1C, fasting blood glucose, and body weight, while also potentially delaying the progression to type 2 diabetes mellitus in prediabetic patients. The gene discussed is GLP1R; the disease is diabetes mellitus.